Inicio › Trastorno depresivo mayor › Pensilvania
Ensayos clínicos de Trastorno depresivo mayor en Pensilvania
24 estudios sobre Trastorno depresivo mayor buscan participantes en Pensilvania.
Ciudades en Pensilvania
Texto oficial del estudio (inglés)
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Adams Clinical Philadelphia, Philadelphia
- Flourish Research Philadelphia, Philadelphia
ReclutandoFase 3
Edades de 18 a 85 · Todos los sexos · Actualizado el 13 nov 2026 · NCT06793397Precision Depression Adalimumab Trial
- University of Pennsylvania, Philadelphia
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07845604A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Allentown
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 10 nov 2026 · NCT07065240A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Adams Clinical Philadelphia, Philadelphia
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 9 nov 2026 · NCT07592689A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Penn Medicine: University of Pennsylvania Health System, Philadelphia
- Suburban Research Associates, West Chester
ReclutandoFase 3
Edades de 18 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT07412756Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- University of Pennsylvania, Philadelphia
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 3 nov 2026 · NCT06559306A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Adams Clinical Philadelphia, Philadelphia
- Penn Medicine: University of Pennsylvania Health System, Philadelphia
- Suburban Research Associates, West Chester
ReclutandoFase 3
Edades de 18 a 75 · Todos los sexos · Actualizado el 3 nov 2026 · NCT07775300Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Pennsylvania - Perelman School of Medicine, Philadelphia
ReclutandoFase 3
Edades de 18 a 65 · Todos los sexos · Actualizado el 3 nov 2026 · NCT05850689A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- University of Pennsylvania, Philadelphia
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 3 nov 2026 · NCT07573176Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Philadelphia
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT06966401Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
ReclutandoFase 3
Edades de 18 a 75 · Todos los sexos · Actualizado el 23 oct 2026 · NCT07226232A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Philadelphia
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT07196501Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- Pennsylvania Hospital, Philadelphia
Reclutando
Edades de 22 a 70 · Todos los sexos · Actualizado el 16 oct 2026 · NCT06423430A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Allentown
- Draig Clinical Site, Media
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 14 oct 2026 · NCT07610473Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments
- Bellefield Towers, Pittsburgh
Reclutando
Edades de 18 a 55 · Todos los sexos · Actualizado el 13 oct 2026 · NCT06976840Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine
- University of Pennsylvania, Philadelphia
ReclutandoFase 1 temprana
Edades de 25 a 65 · Todos los sexos · Actualizado el 7 oct 2026 · NCT06788249Decoding and Modulating Affective Brain States
- University of Pennsylvania, Philadelphia
ReclutandoIndica pago para participantes
Edades de 18 a 65 · Todos los sexos · Actualizado el 3 sept 2026 · NCT05437705NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Philadelphia
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 ago 2026 · NCT06963021Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Lehigh Center for Clinical Research, Allentown
ReclutandoFase 2
Edades de 18 a 64 · Todos los sexos · Actualizado el 3 ago 2026 · NCT06547489A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Lehigh Center for Clinical Research, Allentown
- Adams Clinical, Philadelphia
ReclutandoFase 2
Edades de 18 a 64 · Todos los sexos · Actualizado el 27 jul 2026 · NCT07115329Triage Survey for Psychiatry Research Eligibility
- Adams Clinical, Philadelphia, Philadelphia
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 may 2026 · NCT05800925Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
- University of Pittsburgh, Pittsburgh
Reclutando
Edades de 18 a 55 · Todos los sexos · Actualizado el 4 mar 2026 · NCT05703256Taking Action for College Students
- Temple University, Philadelphia
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 dic 2025 · NCT06700902Neurofeedback to Treat Depression - 2
- Center for Neuromodulation in Depression and Stress, Philadelphia
Reclutando
Edades de 18 a 65 · Todos los sexos · Actualizado el 4 dic 2025 · NCT07159061De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.